• ASCO 2014 Meeting Highlights
  • Earn CME Now
  • Register Now
  • ONS 2014: Highlights in Myltiple Myeloma - View Today!
  • New Options, New Hope: Recent Chemotherapeutic Advances in Metastatic Pancreatic Cancer
  • FAQ's

    FAQ Library

    Respected thought leaders answer frequently asked questions on issues important to your practice – available in video, audio, and transcript formats.

  • FAQ's

    Meeting Highlights

    Video and written highlights from major annual meetings regarding the most current multiple myeloma clinical study findings–one of our most popular features!

  • FAQ's

    CE Activities

    Accredited activities that focus on the assessment, diagnosis and treatment of multiple myeloma. Each activity highlights clinically relevant, timely and accurate scientific information, designed to support you in your search for additional education and improved patient care.

  • Recognizing the Signs and Symptoms of Multiple Myeloma in the Primary Care Setting

What's New

ASCO Meeting Highlights
ASCO 2014: Highlights in Multiple Myeloma
Noopur Raje, MD – Moderator; P. Leif Bergsagel, MD; A. Keith Stewart, MB ChB; Sagar Lonial, MD; Andrzej Jakubowiak, MD, PhD; Jesus San Miguel, MD, PhD
ONS Meeting Highlights
ONS 2014: Highlights in Multiple Myeloma
Beth Faiman, PhDc, RN, MSN, APRN-BC, AOCN®; Sandra E. Kurtin, RN, MS, AOCN®, ANP-C; Page Bertolotti, RN, BSN, OCN; Elizabeth Finley-Oliver, RN, OCN; Joseph D. Tariman, PhD
CE Activity
What Are the Priorities for the Patient with Renal Impairment and Hypercalcemia?
David Vesole, MD, PhD, FACP
CE Activity
When Should I Start Treatment in Relapsed/Refractory Myeloma and How Do I Choose a Therapy?
Marie Sabo Recine, MS, and Eugene R. Tombler, PhD – Contributing authors
Nurse Specific CNE Activity
Case Series 1 – Is this Multiple Myeloma? What to do for Patients Who Delay Stem Cell Transplant
Parameswaran Hari, MD and Sergio Giralt, MD
Clinical Trials
Highlighted Trials 2013: Phase II Trial with Elotuzumab Plus Lenalidomide and Low-Dose Dexamethasone in the RR Setting
Clinical Trials
Highlighted Trials 2013: A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone in Relapsed/Refractory Patients